MicroRNAs: Allies or Foes in erythropoiesis?

Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Journal of Cellular Physiology (Impact Factor: 3.87). 01/2012; 227(1):7-13. DOI: 10.1002/jcp.22729
Source: PubMed

ABSTRACT MicroRNAs are small non-coding RNAs that negatively regulate gene expression through mRNA degradation or translational repression. It is becoming increasingly recognized that miRNAs play central roles in almost all cellular processes, and especially during development. The function of miRNAs in hematopoiesis, including erythropoiesis, is beginning to be elucidated. In this review, we will focus on what is known about miRNA function in various aspects of erythropoiesis and red cell physiology.

Download full-text


Available from: Thalia Papayannopoulou, Aug 08, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are small, non-protein coding transcripts involved in many cellular and physiological mechanisms. Recently, a new class of miRNA called 'circulating miRNAs' was found in cell-free body fluids such as plasma and urine. Circulating miRNAs have been shown to be very stable, specific, and sensitive biomarkers. In this paper, we investigate whether circulating miRNAs can serve as biomarkers for erythropoiesis-stimulating agent abuse. To this end, we analyzed miRNA levels in plasma by miRNA microarrays and quantitative real-time polymerase chain reaction (PCR). Plasma samples are derived from a clinical study with healthy subjects injected with erythropoiesis-stimulating agent (C.E.R.A.). Based on microarray results, we observed a significant difference in the levels of miRNAs in plasma after C.E.R.A. injection. We demonstrated that a specific miRNA, miR-144, exhibit a high increase that lasts 27 days after C.E.R.A. stimulation. Considering the fact that miR-144 is an essential erythropoiesis agent in different organisms, these findings suggest the possibility of using miR-144 as a sensitive and informative biomarker to detect C.E.R.A. abuse.
    Drug Testing and Analysis 11/2011; 3(11-12):771-6. DOI:10.1002/dta.370 · 2.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are a class of small regulatory noncoding RNAs that modulate the expression of their target genes through either mRNA degradation or inhibition of protein translation. In recent years, miRNAs have been shown to be critical regulators of hematopoiesis and have important roles in the differentiation of specific lineages. Here, we summarize our current understanding of miRNAs involved in hematopoiesis with a focus on the role of miRNAs in regulating erythroid and megakaryocytic differentiation and megakaryocyte-erythroid progenitor lineage commitment.Leukemia advance online publication, 19 June 2012; doi:10.1038/leu.2012.137.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 05/2012; 26(11). DOI:10.1038/leu.2012.137 · 9.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Polycythemia vera (PV) and essential thrombocythemia (ET) are the two most common myeloproliferative neoplasms. The same JAK2(V617F) mutation can be found in both disorders and is able to recapitulate many of the phenotypic abnormalities of these diseases in the murine models. The disease phenotype is also influenced by other unknown genetic or epigenetic factors. MicroRNAs (miRNA) are 18-24 nucleotides single-stranded non-protein-coding RNAs that function primarily as gene repressors by binding to their target messenger RNAs. We performed miRNA expression profiling by oligonucleotide microarray analysis in purified peripheral blood CD34+ cells from eight JAK2(V617F)-positive PV patients and six healthy donors. A quantitative reverse-transcription polymerase chain reaction assay was used to verify differential miRNA expression. Since erythrocytosis is the only feature that distinguishes PV from ET, we also compared specific miRNA expression in the nucleated erythroid cells directly descended from the early erythroid progenitor cells of PV and ET patients. Our data indicate that significant miRNA deregulation occurs in PV CD34+ cells and confirm a genetic basis for the gender-specific differences that characterize PV with respect to miRNA. The results of our study also suggest that deregulated miRNAs may represent an important mechanism by which the PV erythrocytosis and ET thrombocytosis phenotypes are determined.
    Blood Cells Molecules and Diseases 12/2012; 50(3). DOI:10.1016/j.bcmd.2012.11.009 · 2.33 Impact Factor
Show more